Endpoints News· @endpts · X·· 3 小时前精选AI 评分72
AI 导读
Endeavor宣布其IPF（特发性肺纤维化）药物在一项2b期试验中达到主要终点。公司称该药可能逆转疾病，而不仅仅是延缓进展。原文未披露具体药物名称、疗效数据或试验细节。
推荐理由
原文给出IPF药物2b期试验达到主要终点的信息，读者可关注其宣称的逆转疾病而非仅延缓进展这一差异。
正文
Endeavor says its IPF drug met the main goal of a Phase 2b trial and could reverse the disease, not just slow it. https://endpoints.news/endeavor-notches-major-mid-stage-trial-win-says-ipf-drug-can-reverse-disease/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源：Endpoints News · x.com